PetMed Express, Inc.(PETS)Earnings, Financials & Key Ratios

PETS•NASDAQ

$2.31

$49M mkt cap·Price updated May 6, 2026

SectorHealthcare IndustryPharmaceuticals Sub-IndustryDigital Health and Online Pharmacy

AboutPetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.Show more

Revenue$227M-17.2%
EBITDA$6M+5760.6%
Net Income-$6M+16.0%
EPS (Diluted)-0.30+18.9%
Gross Margin30.46%+7.4%
EBITDA Margin2.43%+6976.4%
Operating Margin-0.67%+73.5%
Net Margin-2.76%-1.5%
ROE-6.9%+4.5%
ROIC-3.09%+85.3%
Debt/Equity0.01-22.2%

Technical→

PETS Key Insights

PetMed Express, Inc. (PETS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value
✓Efficient asset utilization: 1.5x turnover

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

PETS Price & Volume

PetMed Express, Inc. (PETS) stock price & volume — 10-year historical chart

Loading chart...

PETS Growth Metrics

PetMed Express, Inc. (PETS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-0.11%

5 Years-4.39%

3 Years-6.02%

TTM-24.81%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-5613.71%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-4383.61%

Return on Capital

10 Years22.94%

5 Years7.43%

3 Years-1.05%

Last Year-1.67%

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
CHWYChewy, Inc.Direct Competitor	10.19B	24.59	27.02	6.4%	1.22%	38.76%	1.92
WOOFPetco Health and Wellness Company, Inc.Direct Competitor	749.14M	2.74	86.44	-2.53%	0.15%	0.79%	1.18
FRPTFreshpet, Inc.Direct Competitor	2.69B	54.93	20.80	13.01%	17.63%	16.98%	0.46
HIMSHims & Hers Health, Inc.Product Competitor	6.94B	26.88	52.71	59%	5.47%	23.73%	2.07
TDOCTeladoc Health, Inc.Product Competitor	1.23B	6.80	-5.96	-1.54%	-6.81%	-12.37%	0.75
GOCOGoHealth, Inc.Product Competitor	12.75M	1.01	-1.53	8.74%	-26.96%	-64.38%	1.15
RXRXRecursion Pharmaceuticals, Inc.Product Competitor	1.53B	3.43	-2.38	26.92%	-8.44%	-54.32%	0.07
ZTSZoetis Inc.Supply Chain	46.95B	111.22	18.48	2.28%	28.23%	58.23%	2.85

Compare PETS vs Peers

PetMed Express, Inc. (PETS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CHWY

Most directly comparable listed peer for PETS.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare PETS against a more recognizable public peer.

Peer Set

Compare Top 5

vs CHWY, WOOF, FRPT, HIMS

PETS Income Statement

PetMed Express, Inc. (PETS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Sales/Revenue	249.18M	273.8M	283.42M	284.13M	303.58M	273.42M	256.58M	274.1M	226.97M	194.99M
Revenue Growth %	6.18%	9.88%	3.51%	0.25%	6.85%	-9.94%	-6.16%	6.83%	-17.19%	-24.81%
Cost of Goods Sold	169.86M	175.99M	188.1M	202.88M	219.27M	198.08M	185.84M	196.38M	157.84M	136.6M
COGS % of Revenue	68.17%	64.28%	66.37%	71.4%	72.23%	72.45%	72.43%	71.65%	69.54%	-
Gross Profit	79.31M▲ 0%	97.81M▲ 23.3%	95.31M▼ 2.5%	81.25M▼ 14.8%	84.32M▲ 3.8%	75.34M▼ 10.6%	71.01M▼ 5.7%	77.71M▲ 9.4%	69.14M▼ 11.0%	58.39M▲ 0%
Gross Margin %	31.83%	35.72%	33.63%	28.6%	27.77%	27.55%	27.68%	28.35%	30.46%	29.94%
Gross Profit Growth %	3.96%	23.32%	-2.55%	-14.76%	3.78%	-10.65%	-5.74%	9.43%	-11.03%	-
Operating Expenses	41.83M	45.67M	49.14M	50.27M	53.78M	49.63M	64.68M	84.67M	70.67M	80.11M
OpEx % of Revenue	16.79%	16.68%	17.34%	17.69%	17.72%	18.15%	25.21%	30.89%	31.13%	-
Selling, General & Admin	40.46M	43.55M	46.91M	48.01M	49.93M	49.63M	68.9M	79.75M	62.43M	72.98M
SG&A % of Revenue	16.24%	15.9%	16.55%	16.9%	16.45%	18.15%	26.85%	29.1%	27.5%	-
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	1.37M	2.13M	2.23M	2.26M	3.85M	0	-4.21M	4.92M	8.24M	3M
Operating Income	37.48M▲ 0%	52.14M▲ 39.1%	46.17M▼ 11.4%	30.98M▼ 32.9%	30.53M▼ 1.4%	25.71M▼ 15.8%	6.55M▼ 74.5%	-6.96M▼ 206.3%	-1.53M▲ 78.0%	-21.72M▲ 0%
Operating Margin %	15.04%	19.04%	16.29%	10.9%	10.06%	9.4%	2.55%	-2.54%	-0.67%	-11.14%
Operating Income Growth %	15.73%	39.09%	-11.44%	-32.91%	-1.44%	-15.79%	-74.52%	-206.27%	78.02%	-
EBITDA	38.85M	54.26M	48.4M	33.23M	32.96M	28.45M	10.1M	94K	5.51M	-13.5M
EBITDA Margin %	15.59%	19.82%	17.08%	11.7%	10.86%	10.4%	3.94%	0.03%	2.43%	-6.92%
EBITDA Growth %	17.17%	39.66%	-10.8%	-31.33%	-0.83%	-13.68%	-64.51%	-99.07%	5760.64%	-371.42%
D&A (Non-Cash Add-back)	1.37M	2.13M	2.23M	2.26M	2.43M	2.74M	3.55M	7.06M	7.04M	8.22M
EBIT	37.92M	53.79M	49.12M	33.89M	30.53M	27.07M	7.45M	-6.27M	-330K	-47.4M
Net Interest Income	141K	658K	1.86M	1.75M	-896K	335K	450K	511K	0	-619K
Interest Income	141K	658K	1.86M	1.75M	314K	335K	450K	511K	0	28K
Interest Expense	0	0	0	0	1.21M	0	0	0	0	647K
Other Income/Expense	441K	1.65M	2.95M	2.92M	419K	1.36M	894K	689K	943K	-27.15M
Pretax Income	37.92M▲ 0%	53.79M▲ 41.8%	49.12M▼ 8.7%	33.89M▼ 31.0%	30.95M▼ 8.7%	27.07M▼ 12.5%	7.45M▼ 72.5%	-6.27M▼ 184.3%	-587K▲ 90.6%	-48.88M▲ 0%
Pretax Margin %	15.22%	19.65%	17.33%	11.93%	10.19%	9.9%	2.9%	-2.29%	-0.26%	-25.07%
Income Tax	14.11M	16.51M	11.38M	8.04M	7.03M	5.97M	2.31M	1.19M	5.68M	6.14M
Effective Tax Rate %	37.19%	30.69%	23.17%	23.73%	22.72%	22.06%	30.96%	-18.99%	-968.31%	-12.57%
Net Income	23.82M▲ 0%	37.28M▲ 56.5%	37.74M▲ 1.2%	25.85M▼ 31.5%	23.92M▼ 7.5%	21.1M▼ 11.8%	5.14M▼ 75.6%	-7.46M▼ 245.2%	-6.27M▲ 16.0%	-55.02M▲ 0%
Net Margin %	9.56%	13.62%	13.32%	9.1%	7.88%	7.72%	2%	-2.72%	-2.76%	-28.22%
Net Income Growth %	15.81%	56.53%	1.23%	-31.5%	-7.47%	-11.79%	-75.64%	-245.21%	15.98%	-5613.71%
Net Income (Continuing)	23.82M	37.28M	37.74M	25.85M	23.92M	21.1M	5.14M	-7.46M	-6.27M	-55.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	1.17▲ 0%	1.82▲ 55.6%	1.84▲ 1.1%	1.29▼ 29.9%	1.52▲ 17.8%	1.04▼ 31.6%	0.25▼ 76.0%	-0.37▼ 248.0%	-0.30▲ 18.9%	-2.63▲ 0%
EPS Growth %	14.71%	55.56%	1.1%	-29.89%	17.83%	-31.58%	-75.96%	-248%	18.92%	-4383.61%
EPS (Basic)	1.18	1.83	1.84	1.29	1.53	1.05	0.25	-0.37	-0.30	-
Diluted Shares Outstanding	20.38M	20.43M	20.49M	20.05M	20.12M	20.36M	20.34M	20.4M	20.6M	20.89M
Basic Shares Outstanding	20.23M	20.35M	20.46M	20.04M	20.06M	20.18M	20.27M	20.4M	20.6M	20.89M
Dividend Payout Ratio	65.11%	46.86%	58.09%	84.34%	94.85%	115.56%	477.37%	-	-	-

PETS Balance Sheet

PetMed Express, Inc. (PETS) balance sheet — assets, liabilities & shareholders' equity

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Total Current Assets	81.78M	105.23M	126.43M	129.02M	161.19M	151M	130.43M	93.65M	78.87M	59.45M
Cash & Short-Term Investments	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.3M	54.72M	36.1M
Cash Only	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.3M	54.72M	36.1M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.81M	2.29M	2.54M	3.84M	2.59M	1.91M	1.74M	3.28M	2.32M	1.97M
Days Sales Outstanding	2.65	3.06	3.27	4.94	3.11	2.55	2.48	4.37	3.73	3.81
Inventory	20.23M	23.34M	21.37M	17.88M	34.42M	32.45M	19.02M	28.56M	16.2M	14.77M
Days Inventory Outstanding	43.47	48.4	41.47	32.18	57.3	59.8	37.36	53.07	37.47	40.83
Other Current Assets	1.02M	882K	1.41M	3.53M	4.5M	681K	4.72M	6.33M	5.63M	6.36M
Total Non-Current Assets	31.02M	29.6M	28M	26.3M	26.31M	25.32M	39.57M	76.24M	69.83M	40.85M
Property, Plant & Equipment	30.16M	28.74M	27.14M	25.45M	25.45M	24.46M	26.18M	28.09M	29.82M	29.08M
Fixed Asset Turnover	8.26x	9.53x	10.44x	11.17x	11.93x	11.18x	9.80x	9.76x	7.61x	6.60x
Goodwill	0	0	0	0	0	0	0	26.66M	26.66M	0
Intangible Assets	860K	860K	860K	860K	860K	860K	5.86M	11.2M	13.35M	6.47M
Long-Term Investments	0	0	0	25.52M	25.55M	24.27M	5M	5.3M	0	15.9M
Other Non-Current Assets	0	0	-28M	-26.3M	-26.31M	-25.32M	-5M	4.99M	0	0
Total Assets	112.81M▲ 0%	134.84M▲ 19.5%	154.43M▲ 14.5%	155.32M▲ 0.6%	187.5M▲ 20.7%	176.32M▼ 6.0%	170M▼ 3.6%	169.88M▼ 0.1%	148.7M▼ 12.5%	100.3M▲ 0%
Asset Turnover	2.21x	2.03x	1.84x	1.83x	1.62x	1.55x	1.51x	1.61x	1.53x	1.55x
Asset Growth %	24.96%	19.53%	14.53%	0.58%	20.71%	-5.96%	-3.58%	-0.07%	-12.47%	-90.94%
Total Current Liabilities	18.36M	18.11M	18.63M	24.34M	44.94M	33.2M	57.51M	72.16M	62.77M	56.68M
Accounts Payable	15.22M	15.27M	16.27M	19.66M	39.55M	27.5M	25.21M	37.02M	23.56M	19.12M
Days Payables Outstanding	32.71	31.68	31.58	35.37	65.83	50.67	49.51	68.81	54.49	49.21
Short-Term Debt	0	0	0	0	0	0	0	459K	461K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	2.6M	2.08M	5.34M
Other Current Liabilities	1.06M	431K	613K	1.64M	1.83M	4.56M	30.74M	30.54M	36.66M	0
Current Ratio	4.46x	5.81x	6.79x	5.30x	3.59x	4.55x	2.27x	1.30x	1.26x	1.26x
Quick Ratio	3.35x	4.52x	5.64x	4.57x	2.82x	3.57x	1.94x	0.90x	1.00x	1.00x
Cash Conversion Cycle	13.41	19.78	13.16	1.75	-5.43	11.68	-9.67	-11.37	-13.29	-4.56
Total Non-Current Liabilities	1.09M	996K	1.12M	970K	1.28M	936K	2.53M	995K	798K	554K
Long-Term Debt	0	0	0	0	0	0	0	0	535K	0
Capital Lease Obligations	0	0	0	0	0	0	995K	995K	0	1.36M
Deferred Tax Liabilities	1.09M	996K	1.12M	970K	1.28M	936K	2.53M	0	263K	789K
Other Non-Current Liabilities	0	0	0	0	0	0	-995K	0	0	0
Total Liabilities	19.44M	19.11M	19.75M	25.31M	46.22M	34.13M	60.04M	73.15M	63.57M	57.24M
Total Debt	0	0	0	0	0	0	995K	1.45M	996K	768K
Net Debt	-58.73M	-77.94M	-100.53M	-103.76M	-118.72M	-111.08M	-103.09M	-53.84M	-53.72M	-35.33M
Debt / Equity	-	-	-	-	-	-	0.01x	0.02x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	0.10x	15.47x	0.18x	-0.06x
Net Debt / EBITDA	-1.51x	-1.44x	-2.08x	-3.12x	-3.60x	-3.90x	-10.21x	-572.79x	-9.75x	-9.75x
Interest Coverage	-	-	-	-	25.23x	-	-	-	-	-73.26x
Total Equity	93.37M▲ 0%	115.73M▲ 24.0%	134.68M▲ 16.4%	130.01M▼ 3.5%	141.28M▲ 8.7%	142.19M▲ 0.6%	109.97M▼ 22.7%	96.73M▼ 12.0%	85.13M▼ 12.0%	43.06M▲ 0%
Equity Growth %	12.23%	23.95%	16.37%	-3.47%	8.67%	0.64%	-22.66%	-12.04%	-11.99%	-116.1%
Book Value per Share	4.58	5.66	6.57	6.48	7.02	6.98	5.41	4.74	4.13	2.06
Total Shareholders' Equity	93.37M	115.73M	134.68M	130.01M	141.28M	142.19M	109.97M	96.73M	85.13M	43.06M
Common Stock	21K	21K	21K	20K	20K	21K	21K	21K	21K	21K
Retained Earnings	86.53M	106.32M	122.17M	126.18M	134.14M	130.5M	91.66M	71.56M	66.54M	23.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-4.05M	-6.17M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

PETS Cash Flow Statement

PetMed Express, Inc. (PETS) cash flow — operating, investing & free cash flow history

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Cash from Operations	47.2M	37.38M	45.14M	38.84M	40.08M	18.5M	27.8M	4.32M	4.72M	4.72M
Operating CF Margin %	18.94%	13.65%	15.93%	13.67%	13.2%	6.77%	10.84%	1.57%	2.08%	-
Operating CF Growth %	124.22%	-20.81%	20.76%	-13.94%	3.17%	-53.84%	50.3%	-84.47%	9.29%	-381.02%
Net Income	23.82M	37.28M	37.74M	25.85M	30.6M	21.1M	233K	-7.46M	-6.27M	-55.02M
Depreciation & Amortization	1.37M	2.13M	2.23M	2.26M	2.43M	2.74M	3.55M	7.06M	7.04M	8.43M
Stock-Based Compensation	1.94M	2.58M	3.1M	2.82M	3.31M	4.55M	6.62M	6.87M	-6.59M	1.88M
Deferred Taxes	1.95M	-92K	125K	-151K	311K	-345K	-1.56M	292K	5.25M	465K
Other Non-Cash Items	421K	112K	85K	191K	130K	165K	5.05M	324K	1.56M	41.98M
Working Capital Changes	17.71M	-4.63M	1.87M	7.87M	3.3M	-9.71M	13.92M	-2.76M	3.72M	-3.11M
Change in Receivables	-505K	-596K	-335K	-1.49M	1.13M	509K	-41K	-1.74M	601K	276K
Change in Inventory	5.36M	-3.11M	1.97M	3.49M	-16.54M	1.97M	13.43M	-6.42M	12.35M	578K
Change in Payables	10.22M	53K	1M	3.38M	19.89M	-12.05M	-2.29M	6.1M	-13.46M	-13.97M
Cash from Investing	-10.6M	-703K	-620K	-2.31M	-2.43M	-1.75M	-10.26M	-40.67M	-5.11M	-5.99M
Capital Expenditures	-10.6M	-703K	-620K	-2.31M	-2.43M	-1.75M	-5.26M	-4.51M	-5.11M	-5.99M
CapEx % of Revenue	4.26%	0.26%	0.22%	0.81%	0.8%	0.64%	2.05%	1.65%	2.25%	-
Acquisitions	0	0	0	0	0	0	-5M	-36.16M	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	5M	0	0	0
Cash from Financing	-15.51M	-17.47M	-21.93M	-33.3M	-22.69M	-24.38M	-24.54M	-12.44M	-181K	-292K
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	0	0	-1000K	0	0	0	0	0	0
Dividends Paid	-15.51M	-17.47M	-21.93M	-21.8M	-22.69M	-24.38M	-24.54M	-12.44M	-181K	-25K
Share Repurchases	0	0	0	-11.5M	0	0	0	0	0	0
Other Financing	0	0	0	0	0	0	0	0	0	-267K
Net Change in Cash	21.09M▲ 0%	19.21M▼ 8.9%	22.59M▲ 17.6%	3.23M▼ 85.7%	14.96M▲ 362.6%	-7.64M▼ 151.1%	-6.99M▲ 8.4%	-48.79M▼ 597.6%	-576K▲ 98.8%	-29.54M▲ 0%
Free Cash Flow	36.6M▲ 0%	36.68M▲ 0.2%	44.52M▲ 21.4%	36.53M▼ 17.9%	37.64M▲ 3.0%	16.75M▼ 55.5%	22.54M▲ 34.6%	-194K▼ 100.9%	-395K▼ 103.6%	-33.87M▲ 0%
FCF Margin %	14.69%	13.4%	15.71%	12.86%	12.4%	6.12%	8.79%	-0.07%	-0.17%	-17.37%
FCF Growth %	3865.33%	0.21%	21.38%	-17.94%	3.04%	-55.51%	34.62%	-100.86%	-103.61%	-3589.22%
FCF per Share	1.80	1.79	2.17	1.82	1.87	0.82	1.11	-0.01	-0.02	-0.02
FCF Conversion (FCF/Net Income)	1.98x	1.00x	1.20x	1.50x	1.68x	0.88x	5.41x	-0.58x	-0.75x	0.62x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	11.37M	18.05M	11.05M	7.14M	10.02M	6.08M	4.31M	130K	0	8K

PETS Key Ratios

PetMed Express, Inc. (PETS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	26.98%	35.66%	30.14%	19.53%	17.63%	14.89%	4.08%	-7.22%	-6.9%	-127.77%
Return on Invested Capital (ROIC)	70.11%	107.97%	96.27%	76.93%	93.82%	71.86%	25.87%	-20.98%	-3.09%	-3.09%
Gross Margin	31.83%	35.72%	33.63%	28.6%	27.77%	27.55%	27.68%	28.35%	30.46%	29.94%
Net Margin	9.56%	13.62%	13.32%	9.1%	7.88%	7.72%	2%	-2.72%	-2.76%	-28.22%
Debt / Equity	-	-	-	-	-	-	0.01x	0.02x	0.01x	0.01x
Interest Coverage	-	-	-	-	25.23x	-	-	-	-	-73.26x
FCF Conversion	1.98x	1.00x	1.20x	1.50x	1.68x	0.88x	5.41x	-0.58x	-0.75x	0.62x
Revenue Growth	6.18%	9.88%	3.51%	0.25%	6.85%	-9.94%	-6.16%	6.83%	-17.19%	-24.81%

PETS Frequently Asked Questions

PetMed Express, Inc. (PETS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

PetMed Express, Inc. (PETS) reported $195.0M in revenue for fiscal year 2025. This represents a 1229% increase from $14.7M in 2000.

PetMed Express, Inc. (PETS) saw revenue decline by 17.2% over the past year.

PetMed Express, Inc. (PETS) reported a net loss of $55.0M for fiscal year 2025.

Dividend & Returns

Yes, PetMed Express, Inc. (PETS) pays a dividend with a yield of 0.38%. This makes it attractive for income-focused investors.

PetMed Express, Inc. (PETS) has a return on equity (ROE) of -6.9%. Negative ROE indicates the company is unprofitable.

PetMed Express, Inc. (PETS) had negative free cash flow of $33.9M in fiscal year 2025, likely due to heavy capital investments.

Explore More PETS

PetMed Express, Inc. (PETS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→